Redwood City, CA, United States of America

Kenneth C Cundy

This inventor holds 38 USPTO granted patents and 13 published patent applications, plus 3 CIPO patents and 5 EPO patents, primarily in Prodrug Development. Top assignees: Xenoport, Inc., Arbor Pharmaceuticals, LLC, Other. Active years: 2004-2021.

USPTO Granted Patents = 38 (Patent Applications = 13)

% Patents Active = 28.9

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 3)

Average Co-Inventor Count = 4.0

ph-index = 13

Forward Citations = 449(Granted Patents)

Company Filing History:

Arbor Pharmaceuticals, LLC

patents

1 out of 834,307

Other

patents

Years Active: 2004-2021

Loading Chart...

Areas of Expertise:

Prodrugs

GABA Analogs

Levodopa

Bile-Acid Compounds

Sustained Release

Oral Dosage Forms

Pharmaceutical Compositions

Amino Acid Conjugates

Gemcitabine

Reduced Side Effects

Systemic Bioavailability

Transport Proteins

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10945984 - Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects (2021-03-16),

2. 9949941 - GABA analog prodrug sustained release oral dosage forms (2018-04-24),

3. 8952006 - Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use (2015-02-10),

4. 8906412 - GABA analog prodrug sustained release oral dosage forms (2014-12-09),

5. 8795725 - GABA analog prodrug sustained release oral dosage forms (2014-08-05),

6. 8367722 - Methods of using prodrugs of pregabalin (2013-02-05),

7. 8168623 - Prodrugs of GABA analogs, compositions and uses thereof (2012-05-01),

8. 8163958 - Levodopa prodrugs, and compositions and uses thereof (2012-04-24),

9. 8048917 - Prodrugs of GABA analogs, compositions and uses thereof (2011-11-01),

10. 7956212 - Levodopa prodrugs, and compositions and uses thereof (2011-06-07),

11. 7803785 - Gemcitabine prodrugs, pharmaceutical compositions and uses thereof (2010-09-28),

12. 7790708 - Prodrugs of GABA analogs, compositions and uses thereof (2010-09-07),

13. 7767649 - Amino acid conjugates providing for sustained systemic concentrations of GABA analogues (2010-08-03),

14. 7678782 - Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs (2010-03-16),

15. 7671089 - Levodopa prodrugs, and compositions and uses thereof (2010-03-02),

Title: Innovations and Contributions of Kenneth C. Cundy

Introduction

Kenneth C. Cundy is a prominent inventor based in Redwood City, CA, with an impressive portfolio of 38 patents to his name. His innovative work has significantly contributed to the field of pharmaceuticals, focusing on methods that enhance therapeutic treatments while minimizing side effects.

Latest Patents

Among his recent patents, Cundy's notable inventions include:

1. **Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects** - This patent discloses methods aimed at reducing undesirable side effects during therapeutic treatment using monomethyl fumarate and its prodrugs.

2. **GABA analog prodrug sustained release oral dosage forms** - This patent highlights the development of sustained release oral dosage forms of a gabapentin prodrug, specifically designed to treat or prevent diseases and disorders where gabapentin has therapeutic efficacy.

Career Highlights

Throughout his career, Kenneth C. Cundy has worked with various companies, including Xenoport, Inc. His dedication to pharmaceutical advancements has led him to create pioneering solutions that address critical health challenges.

Collaborations

Cundy has collaborated with notable professionals in the field, including Mark A. Gallop and Cindy X. Zhou. These partnerships have facilitated the sharing of ideas and further propelled the innovative processes essential for groundbreaking pharmaceutical developments.

Conclusion

Kenneth C. Cundy's contributions to the pharmaceutical industry exemplify the spirit of innovation. With a robust patent portfolio and collaborative efforts with industry leaders, he continues to make strides in enhancing therapeutic treatments and improving patient outcomes. His work serves as an inspiration to aspiring inventors in the realm of pharmaceuticals and beyond.